CVS’s stock surges toward a one-year high after profit and revenue beat expectations, amid strength in the pharmacy business, and the full-year outlook was raised.

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

This will enable CVS Pharmacy to provide eligible patients at its 9,000 community health locations with convenient, safe, and affordable access to Novo Nordisk A/S' NVO Wegovy. Guidance ...

CVS Health’s insurance division Aetna will stop ... with Danish drugmaker Novo Nordisk to give its weight loss drug Wegovy preferred access on Caremark’s standard formulary, which covers ...

Citing CVS spokesperson David Whitrap, Bloomberg News reported that “Zepbound will be excluded” in health plans using ... in those plans could switch to Wegovy, while exceptions will be ...

One of the largest benefit managers, CVS Health’s Caremark, made the decision to exclude Zepbound in spite of research that found that it resulted in more weight loss than Wegovy, which will ...

Shares of CVS Health Corp. CVS soared toward a one-year ... Obamacare business and will increase access to weight-loss drug Wegovy as it reported blowout earnings. The company said it decided ...

CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be ...

Starting July 1, CVS said Wegovy will be the preferred weight-loss ... while membership increased by 1.1%. For health services, which include CVS Caremark, revenue increased 7.9% to $43.46 billion ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

Good news, right? Well, kinda. Under CEO David Joyner, a 30-year company veteran who took over in October, the company has ...